Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Combination of involved field radiotherapy for the control of macroscopic disease and CD20
antibody Rituximab for the control of microscopic remainders in other regions in patients
with early stage nodal follicular lymphoma /grade I or II). Evaluation of DFSl and toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Klaus Herfarth - Dr. J. Debus Klaus Herfarth, MD
Collaborators:
German Low Grade Lymphoma Study Group Roche Pharma AG